ABBV Stock Movement Summary AbbVie announced a multi-year voluntary agreement with the U.S. government involving a $100 billion commitment to U.S.-based research, development, and capital investments over the next decade. The agreement includes expanded manufacturing and direct-to-patient delivery initiatives. The company is also launching a three-year effort focused on lowering drug prices while expanding U.S. manufacturing and direct patient care access. The agreement is tied to broader federal drug pricing policy initiatives. Recent analyst activity includes Goldman Sachs maintaining a Neutral rating with a $223 price target on January 28, and Citi adjusting its price target to $230 from $235 on January 27, while maintaining a Neutral rating.
Read full analysisABBV Stock Movement Summary AbbVie announced a multi-year voluntary agreement with the U.S. government involving a $100 billion commitment to U.S.-based research, development, and capital investments over the next decade. The agreement includes expanded manufacturing and direct-to-patient delivery initiatives. The company is also launching a three-year effort focused on lowering drug prices while expanding U.S. manufacturing and direct patient care access. The agreement is tied to broader federal drug pricing policy initiatives. Recent analyst activity includes Goldman Sachs maintaining a Neutral rating with a $223 price target on January 28, and Citi adjusting its price target to $230 from $235 on January 27, while maintaining a Neutral rating.
AbbVie Inc (ABBV) is a publicly traded company in the Healthcare sector.